IRLAB Therapeutics AB (publ) (IRLAB-A) — Capital Reinvestment Ratio

Latest as of September 2021: 0.00x

IRLAB Therapeutics AB (publ) (IRLAB-A) has a Capital Reinvestment Ratio of 0.00x as of September 2021, meaning it reinvests 0% of its operating cash flow (Skr202.83 Million) in capital expenditures (Skr137.00K). Check tangible net worth ratio of IRLAB Therapeutics AB (publ) to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.00x
Capex / Operating Cash Flow

Operating Cash Flow

Skr202.83 Million
SEK

Capital Expenditures

Skr137.00K
SEK

Data as of

Sep 2021
Most recent filing

IRLAB Therapeutics AB (publ) Capital Reinvestment Ratio (2021–2021)

This chart tracks IRLAB Therapeutics AB (publ)'s Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see how efficiently does IRLAB Therapeutics AB (publ) generate cash.

Annual Capital Reinvestment Ratio for IRLAB Therapeutics AB (publ) (2021–2021)

Year-by-year Capital Reinvestment Ratio for IRLAB Therapeutics AB (publ) from 2021 to 2021. See IRLAB Therapeutics AB (publ) free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (SEK) Capital Expenditures YoY Change
2021 0.01x Skr128.64 Million Skr708.00K —
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow